ED90 of esketamine in combination with flurbiprofen to Prevent body movement in ambulatory hysteroscopic surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400080615

Enrollment

Unknown

Registered

2024-02-02

Start date

2024-02-15

Completion date

Unknown

Last updated

2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

endometrial polyp

Interventions

Test group:Flurbiprofen axetil was injected, rimazolam and esketamine were pumped.

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-64 years 2. BMI 18-28 kg/m2 3. Patients with ASA grade I-II 4. The subjects understood and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with severe adhesion of cervical and uterine cavity 2. Patients with respiratory and circulatory dysfunction 3. Patients with hepatic and renal dysfunction 4. The patient is allergic to research drugs 5. Recently used sedative and analgesic drugs 6. People with neuropsychiatric diseases

Design outcomes

Primary

Measure	Time frame
the 90% effective dose;	—

Secondary

Measure	Time frame
visual analogue scale Scoring;	—

Countries

China

Contacts

Public ContactWang Zhihua

Hainan General Hospital

13876012831@163.com+86 138 7601 2831

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026